Publication:
MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms

dc.contributor.authorSoldevilla, Beatriz
dc.contributor.authorLens-Pardo, Alberto
dc.contributor.authorEspinosa-Olarte, Paula
dc.contributor.authorCarretero-Puche, Carlos
dc.contributor.authorMolina-Pinelo, Sonia
dc.contributor.authorRobles, Carlos
dc.contributor.authorBenavent, Marta
dc.contributor.authorGomez-Izquierdo, Lourdes
dc.contributor.authorFierro-Fernández, Marta
dc.contributor.authorMorales-Burgo, Patricia
dc.contributor.authorJimenez-Fonseca, Paula
dc.contributor.authorAnton-Pascual, Beatriz
dc.contributor.authorRodriguez-Gil, Yolanda
dc.contributor.authorTeijo-Quintans, Ana
dc.contributor.authorLa Salvia, Anna
dc.contributor.authorRubio-Cuesta, Beatriz
dc.contributor.authorRiesco-Martínez, Maria C
dc.contributor.authorGarcia-Carbonero, Rocio
dc.contributor.authorGarcía-Carbonero, Rocio
dc.contributor.authorLens‐Pardo, Alberto
dc.contributor.authorEspinosa‐Olarte, Paula
dc.contributor.authorCarretero‐Puche, Carlos
dc.contributor.authorMolina‐Pinelo, Sonia
dc.contributor.authorGomez‐Izquierdo, Lourdes
dc.contributor.authorFierro‐Fernández, Marta
dc.contributor.authorMorales‐Burgo, Patricia
dc.contributor.authorJimenez‐Fonseca, Paula
dc.contributor.authorAnton‐Pascual, Beatriz
dc.contributor.authorRodriguez‐Gil, Yolanda
dc.contributor.authorTeijo‐Quintans, Ana
dc.contributor.authorRubio‐Cuesta, Beatriz
dc.contributor.authorRiesco‐Martínez, Maria C.
dc.contributor.authorGarcia‐Carbonero, Rocio
dc.contributor.funderISCIII-Red de Biobancos y Biomodeloses_ES
dc.contributor.funderAsociación Española Contra el Cáncer
dc.contributor.funderInstituto de Salud Carlos III
dc.contributor.funderJunta de Andaluciaes_ES
dc.date.accessioned2024-09-16T08:17:06Z
dc.date.available2024-09-16T08:17:06Z
dc.date.issued2023-04
dc.description.abstractNeuroendocrine neoplasms (NENs) are mutationally quiet (low number of mutations/Mb), and epigenetic mechanisms drive their development and progression. We aimed at comprehensively characterising the microRNA (miRNA) profile of NENs, and exploring downstream targets and their epigenetic modulation. In total, 84 cancer-related miRNAs were analysed in 85 NEN samples from lung and gastroenteropancreatic (GEP) origin, and their prognostic value was evaluated by univariate and multivariate models. Transcriptomics (N�=�63) and methylomics (N�=�30) were performed to predict miRNA target genes, signalling pathways and regulatory CpG sites. Findings were validated in The Cancer Genome Atlas cohorts and in NEN cell lines. We identified a signature of eight miRNAs that stratified patients in three prognostic groups (5-year survival of 80%, 66% and 36%). Expression of the eight-miRNA gene signature correlated with 71 target genes involved in PI3K-Akt and TNF?-NF-kB signalling. Of these, 28 were associated with survival and validated in silico and in vitro. Finally, we identified five CpG sites involved in the epigenetic regulation of these eight miRNAs. In brief, we identified an 8-miRNA signature able to predict survival of patients with GEP and lung NENs, and identified genes and regulatory mechanisms driving prognosis in NEN patients.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThe authors would like to thank the donors and the Hospital Universitario Virgen del Rocio-Instituto de Biomedicina de Sevilla Biobank (Andalusian Public Health System Biobank and ISCIII-Red de Biobancos y Biomodelos-ISCIII-PT20/00069) for the human specimens used in this study. Carolina Castilla, the HUVR biobank manager, is especially thanked for her excellent work and invaluable help to facilitate all facets of this research. We would also like to thank Dr Justo Castano (Instituto Maimonides de Investigacion Biomedica de Cordoba) for kindly providing us with the BON-1 cell line. Finally, we would also like to thank all the funding agencies. BS is funded by the AECC (POSTDO46SOLD, Spain). AL-P is funded by the Instituto de Salud Carlos III (PFIS; FI20/00131). ALS is funded by the Instituto de Salud Carlos III (Contrato Rio Hortega). CC-P was partially funded by CAM (PEJD-2016-PRE/BMD-2666). BR-C was partially funded by CAM (PEJD-2017-PRE/BMD-4981). MCR-M is funded by the AECC (CLSEN19003RIES). SM-P was supported by the Consejeria de Salud y Familias of the Junta de Andalucia through the Nicolas Monardes' program (RC-0004-2020).es_ES
dc.format.number4es_ES
dc.format.page582es_ES
dc.format.volume17es_ES
dc.identifier.citationMol Oncol . 2023 ;17(4):582-597.es_ES
dc.identifier.doi10.1002/1878-0261.13393es_ES
dc.identifier.e-issn1878-0261es_ES
dc.identifier.issn1574-7891es_ES
dc.identifier.journalMolecular oncologyes_ES
dc.identifier.pubmedID36795001es_ES
dc.identifier.urihttps://hdl.handle.net/20.500.12105/23108
dc.language.isoenges_ES
dc.publisherWiley
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/FI20/00131es_ES
dc.relation.publisherversionhttps://doi.org/10.1002/1878-0261.13393es_ES
dc.repisalud.institucionCNIOes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshMicroRNAses_ES
dc.subject.meshNeuroendocrine Tumorses_ES
dc.subject.meshPancreatic Neoplasmses_ES
dc.subject.meshIntestinal Neoplasmses_ES
dc.subject.meshStomach Neoplasmses_ES
dc.subject.meshHumanses_ES
dc.subject.meshPrognosises_ES
dc.subject.meshEpigenesis, Genetices_ES
dc.subject.meshPhosphatidylinositol 3-Kinaseses_ES
dc.titleMicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasmses_ES
dc.typeresearch articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication05dea480-3152-422b-a1cd-e13effd4b7fc
relation.isAuthorOfPublication.latestForDiscovery05dea480-3152-422b-a1cd-e13effd4b7fc
relation.isFunderOfPublication453a1189-9bca-4be8-8d60-695f50fe028b
relation.isFunderOfPublication7d739953-4b68-4675-b5bb-387a9ab74b66
relation.isFunderOfPublication.latestForDiscovery453a1189-9bca-4be8-8d60-695f50fe028b
relation.isPublisherOfPublicationd81e762a-95f7-4917-88a1-8004b3b8caa7
relation.isPublisherOfPublication.latestForDiscoveryd81e762a-95f7-4917-88a1-8004b3b8caa7

Files